Indications
Prevention and treatment of haemorrhage or surgical bleeding in adults (age 18 years and older) with von Willebrand disease (VWD), when desmopressin (DDAVP) treatment alone is ineffective or contraindicated. Veyvondi should not be used in the treatment of Haemophilia A.
Composition
- Active substance
- vonicog alfa
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Veyvondi
- Active substance
- vonicog alfa
- ATC code
- B02BD10
- Therapeutic area
- von Willebrand Diseases
- Marketing authorisation holder
- Baxalta Innovations GmbH
- Status